We provide you with 20 years of free, institutional-grade data for TNYA stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of TNYA. Explore the full financial landscape of TNYA stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2023-11-08 | 1858848 | TNYA | 10-Q | Url |
| 2023-08-09 | 1858848 | TNYA | 10-Q | Url |
| 2023-05-10 | 1858848 | TNYA | 10-Q | Url |
| 2023-03-08 | 1858848 | TNYA | 10-K | Url |
| 2022-11-10 | 1858848 | TNYA | 10-Q | Url |
| 2022-08-10 | 1858848 | TNYA | 10-Q | Url |
| 2022-05-11 | 1858848 | TNYA | 10-Q | Url |
| 2022-03-23 | 1858848 | TNYA | 10-K | Url |
| 2021-11-10 | 1858848 | TNYA | 10-Q | Url |
| 2021-09-08 | 1858848 | TNYA | 10-Q | Url |
| 2021-07-09 | 1858848 | TNYA | S-1 | Url |
Tenaya Therapeutics(NASDAQ:TNYA) 
Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a ...
Website: http://www.tenayatherapeutics.com
Founded: 2016
CEO: Faraz Ali
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about TNYA stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.